Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
HDM201 Added to CT in R/R or Newly Diagnosed AML
NCT03760445 · Novartis Pharmaceuticals · PHASE1/PHASE2 · withdrawn · last registry update 2020-01-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “It was determined that the study design may not be optimal given the changing AML treatment landscape.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TP53 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-02Also stopped (terminated): MultiVir, Inc., Ad-P53 + Xeloda (NCT02842125)
- 2020-05-18Also stopped (terminated): Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT02624986)
- 2020-04-29Results posted on the registry: Hoffmann-La Roche, Idasanutlin + Obinutuzumab (NCT02624986)
- 2019-07-31Also stopped (terminated): Aprea Therapeutics, APR-246 + Dabrafenib (NCT03391050)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision